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Background: HIV-1 is decorated with trimeric glycoprotein spikes that enable infection by engaging CD4 and a
chemokine coreceptor, either CCR5 or CXCR4. The variable loop 3 (V3) of the HIV-1 envelope protein (Env) is the
main determinant for coreceptor usage. The predominant CCR5 using (R5) HIV-1 Env has been intensively studied
in function and structure, whereas the trimeric architecture of the less frequent, but more cytopathic CXCR4 using
(X4) HIV-1 Env is largely unknown, as are the consequences of sequence changes in and near V3 on antigenicity
and trimeric Env structure.
Results: Soluble trimeric gp140 Env constructs were used as immunogenic mimics of the native spikes to analyze
their antigenic properties in the context of their overall 3D structure. We generated soluble, uncleaved, gp140
trimers from a prototypic T-cell line-adapted (TCLA) X4 HIV-1 strain (NL4-3) and a hybrid (NL4-3/ADA), in which the
V3 spanning region was substituted with that from the primary R5 isolate ADA. Compared to an ADA (R5) gp140,
the NL4-3 (X4) construct revealed an overall higher antibody accessibility, which was most pronounced for the CD4
binding site (CD4bs), but also observed for mAbs against CD4 induced (CD4i) epitopes and gp41 mAbs. V3 mAbs
showed significant binding differences to the three constructs, which were refined by SPR analysis. Of interest, the
NL4-3/ADA construct with the hybrid NL4-3/ADA CD4bs showed impaired CD4 and CD4bs mAb reactivity despite
the presence of the essential elements of the CD4bs epitope. We obtained 3D reconstructions of the NL4-3 and the
NL4-3/ADA gp140 trimers via electron microscopy and single particle analysis, which indicates that both constructs inherit
a propeller-like architecture. The first 3D reconstruction of an Env construct from an X4 TCLA HIV-1 strain reveals an open
conformation, in contrast to recently published more closed structures from R5 Env. Exchanging the X4 V3 spanning
region for that of R5 ADA did not alter the open Env architecture as deduced from its very similar 3D reconstruction.
Conclusions: 3D EM analysis showed an apparent open trimer configuration of X4 NL4-3 gp140 that is not modified
by exchanging the V3 spanning region for R5 ADA.
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Open structureBackground
The envelope glycoproteins (Env) of HIV are the key ele-
ments mediating viral entry and represent the major tar-
get for HIV-neutralizing antibodies [1,2]. Env derives
from gp160 precursors that trimerize in the endoplasmic* Correspondence: Ralf.Duerr@nyumc.org
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unless otherwise stated.reticulum and, following cleavage in the Golgi, generate
non-covalently associated trimers of gp120 and gp41
heterodimers. CD4-gp120 binding induces conform-
ational changes in Env, both to expose epitopes for sub-
sequent interaction with coreceptors (CCR5 or CXCR4)
and to activate the gp41 transmembrane subunits for
membrane fusion [3].
According to their coreceptor usage, HIV-1 strains
can be subdivided into CCR5- (R5) and CXCR4-tropic
(X4) variants. While R5 strains are usually transmitted
and predominate at early stages of infection, X4 vari-
ants are found in approximately 50% of subtype BLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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coincide with a rapid CD4 T-cell loss and an acceler-
ated progression to AIDS (see reviews [4,5]). Since the
emergence of X4 variants correlates with a worse prog-
nosis and excludes the use of CCR5 inhibitors in pa-
tients, a better characterization of X4 HIV-1 is an
urgent need. CXCR4 usage is mainly mediated by mu-
tations in the variable loop 3 (V3) of gp120, especially
at the V3 stem, providing an increased positive net
charge [6-8]. In addition to single mutations in V3,
conserved secondary structural constraints have been
shown to contribute to coreceptor choice [9,10]. Be-
sides coreceptor selection and interaction, V3′s con-
served structural constraints render it into one of four
Env regions able to induce cross-clade neutralizing
antibodies [11-14].
Soluble trimeric envelope proteins (gp140), composed
of gp120 linked to the extracellular part of gp41, are use-
ful tools in both immunological and structural studies
[15,16]. Expression of gp140 can be achieved either by
deleting the internal protease cleavage site [17] or by
introduction of an intraprotomeric stabilizing disulfide
bridge (gp140 SOSIP) [18,19]. Recently, efforts were
undertaken to determine the trimeric Env structure of
membrane solubilized or recombinantly expressed gp140
constructs, either in the uncleaved precursor state [20-22]
or in the more mature cleaved state in gp140 SOSIPs
[23-32]. Subramaniam and colleagues demonstrated that
soluble gp140 SOSIP constructs display an almost identi-
cal gp120 molecular arrangement as that observed in
intact HIV-1 virions, both in the unliganded and the CD4
activated state [24]. Mutational analysis of trimeric Env
with deletions of certain variable loops yielded important
information on their location and influence on trimer
stability [25,29].
All the known structural studies so far have character-
ized trimeric Env, either from intact virions or from sol-
uble gp140 constructs derived from R5 HIV-1 or from
SIV. This is complemented by the recent X-ray struc-
tures of the cellular receptors CXCR4 and CCR5, which
interact with Env and thereby induce fusion [33,34].
However, no quaternary structural data is available so far
for X4 HIV-1 Envs. In the present study, we aimed at
characterizing the antigenic and structural characteristics
of trimeric uncleaved gp140 from the prototypic T-cell
line-adapted X4 subtype B strain NL4-3 [35]. Additionally,
a mutant construct was generated, where a V3 spanning
region was exchanged for that of the primary R5 strain
ADA (NL4-3/ADA). The exposed V3 is embedded
between the immunosilent C2 and C3 regions that also
contain elements from the discontinous CD4 binding site
(CD4bs). The exchange of V3 with adjacent small
elements of C2 and C3 should support the display of the
exchanged V3 in a conformational context and highlightthe effects of a combined CD4 binding site originating
from two different HIV-1 strains. Our study aimed at (1)
giving first insights into the quaternary structure of an X4
Env and (2) address consequences of introducing an
extended R5 V3 region into X4 NL4-3 gp140 on antige-
nicity and structure.
Results
Recombinant expression and characterization of NL4-3
and NL4-3/ADA gp140 trimers
Two uncleaved gp140 constructs were generated, NL4-3
gp140 derived from the X4 prototypic HIV-1 subtype B
strain NL4-3 and a hybrid mutant (NL4-3/ADA) with a
V3 spanning region exchanged for that of the R5 sub-
type B strain ADA (Figure 1A). The exchanged region
comprises the complete V3 loop as well as adjacent ele-
ments of C2 (45 aa) and C3 (14 aa). This strategy en-
ables V3 presentation in its parental context, preserves
all N-glycosylation sites as well as adjacent CD4bs ele-
ments, whereas the exchange of threonine for asparagine
at position 277 marginally affects the epitopes of some
CD4bs mAbs (see sequence alignment and epitopes in
Additional files 1 and 2). The recombinantly expressed
gp140 proteins were purified with at least two sequential
purification steps to obtain pure gp140 trimers devoid of
monomers and dimers (Figure 1B, Additional file 3A,B).
Gp140 trimers are composed of gp140 monomers that
migrate around 180 kDa upon DTT treatment in SDS-
PAGE (Figure 1C). The uncleaved R5 ADA gp140 con-
struct was biochemically analyzed in detail [17], and was
also highly purified in its trimeric form for comparison
(see Additional file 3C).
Antibody binding studies by ELISA and SPR
We studied the antigenic properties of our gp140 con-
structs by analyzing the reactivity with monoclonal anti-
bodies (mAbs)/antibody constructs directed against
gp120 V3 (447-52D, D19), CD4bs (CD4-Fc, VRC01,
VRC03, b12, b13, F105), the coreceptor binding site
(CG10, 17b) and gp41 (Md-1, 2F5, 246-D) (Figures 2, 3,
4, Additional file 4 and tables in Additional files 5 and
6). The V3 mAbs D19 and 447-52D reacted with all
gp140 recombinant proteins proving the exposure of V3
in all constructs. MAb D19 preferentially recognizing V3
from X4 strains [36], showed enhanced reactivity with
the X4 NL4-3 gp140 compared to the R5 ADA gp140, as
expected. Consequently, the exchange of the X4 V3 re-
gion for the R5 ADA V3 reduced mAb D19 binding to
levels of the R5 ADA control, as seen by comparable
Amax (Figure 2) and affinity (see KD values in Additional
file 5). In contrast, mAb 447-52D, directed against the
tip of V3, showed similar binding curves for NL4-3 and
ADA gp140, however Amax and affinity for the hybrid
NL4-3/ADA construct were remarkably increased. We
Figure 2 Antibody binding to gp140 constructs in ELISA experiments. The antigenic profiles of the gp140 constructs NL4-3 (X4), ADA (R5) and the
hybrid NL4-3/ADA were evaluated in ELISA experiments with selected monoclonal antibodies (mAbs) against the gp120 V3 loop (447-52D and D19)
[36,37] and the gp41 region (Md-1) [38]. Functional exposure of coreceptor binding epitopes upon CD4 activation was monitored with strictly CD4
dependent mAb CG10 [39]. Where applicable, nonlinear regression fits are shown in the diagrams instead of connected data points. Derived KD values
(PRISM software) are listed in the table of Additional file 5. The purified gp140 timers (NL4-3, ADA and NL4-3/ADA) were compared with gp120
monomers (X4 HXBc2, R5 Bal, R5X4 89.6; Immune Technology) regarding their reactivity with CD4bs mAb b13 (5 nM) and trimer specific gp41 mAb
Md-1 (1:2000 dilution). The data is representative for at least three independent replicate experiments with each data point of the binding curves
determined in triplicates with indicated mAb concentrations. Error bars indicate the standard deviation.
Figure 1 Scheme of the NL4-3 and NL4-3/ADA constructs and protein analysis by SDS-PAGE. (A) Scheme of gp140 expression constructs indicating
cloning of the HIV-1 NL4-3 Env ectodomain with tPA leader sequence and deleted cleavage site. The hybrid construct NL4-3/ADA was generated by exchan-
ging the V3 domain in conjunction with adjacent constant regions of the X4 tropic NL4-3 construct with the respective sequences of the R5 tropic HIV-1
ADA strain. The exchange of the extended V3 region contains two short linear elements of the discontinuous CD4 binding site (see also Additional file 1 and
2). (B, C) SDS-PAGE analysis of purified NL4-3 and NL4-3/ADA gp140 trimers under non-reducing (B) and reducing conditions (+50 mM DTT) (C).
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Figure 3 Kinetics of 447-52D antibody binding to gp140 constructs with SPR measurements. ProteOn XPR36 measurements were
performed with immobilized 447-52D antibody (ligand) and rising concentrations of the different gp140 constructs (analyte). Note the remarkable
slower dissociation of the NL4-3/ADA construct from the 447-52D mAb in contrast to the NL4-3 and ADA construct, which is responsible for its
higher affinity to 447-52D (see also Figure 2 and table of Additional file 6 with listed KD, kon and koff rates).
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inversed binding setup compared to the ELISA experi-
ments, i.e. immobilization of mAb 447-52D and admin-
istration of the gp140 constructs as analytes (Figure 3
and table in Additional file 6). The kon rates of the dif-
ferent gp140 constructs for mAb 447-52D were compar-
able, however we observed a much slower dissociation
of the hybrid NL4-3/ADA from mAb 447-52D with koff
values 5 times lower compared to the other constructs.
This resulted in lower KD values and enhanced binding
signals in end point analyses. Gp41 antibodies Md-1,
2F5 and 246-D were reactive with all gp140 constructs
(Figure 2 and Additional files 4 and 5). The reactivity
with the trimer specific antibody Md-1 confirmed the
trimeric state of our gp140 constructs (Figure 2). Despite
the presence of several antibody epitopes in all gp140constructs, we detected quantitative differences: in most
cases the mAbs showed best binding to NL4-3 gp140,
reduced binding to ADA gp140 and strongly reduced
binding to NL4-3/ADA. Exceptions are mAbs D19, Md-
1 and b13 with comparable binding levels to ADA and
NL4-3/ADA and the V3 mAb 447-52D, which binds by
far best to the hybrid NL4-3/ADA.
ELISA experiments with the coreceptor binding site
antibody CG10, which is strictly CD4 dependent, showed
enhanced binding to NL4-3 gp140 compared to ADA
gp140 after CD4 activation (Figure 2). Accordingly, the
less CD4 dependent CD4i antibody 17b bound preferen-
tially to NL4-3 after CD4 activation, however, similarly
bound to both NL4-3 and ADA gp140 without CD4
activation (Additional file 4). The hybrid NL4-3/ADA
gp140 exhibited only minimal binding to either CD4i
Figure 4 CD4bs antibody binding to gp140 constructs in ELISA experiments. The CD4bs reactivity of the gp140 constructs NL4-3 (X4), ADA
(R5) and the hybrid NL4-3/ADA was evaluated in ELISA experiments with CD4-Fc and five selected monoclonal antibodies: VRC01, VRC03 (both
[40]), b12 [41], b13 [41] and F105 [42]. Where applicable, nonlinear regression fits are shown in the diagrams instead of connected data points.
Derived KD values (PRISM software) are listed in the table of Additional file 5. The data is representative for at least three independent replicate
experiments with each data point of the binding curves determined in triplicates with indicated mAb concentrations. Error bars indicate the
standard deviation.
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the CD4 binding characteristics of our gp140 constructs.
For a detailed CD4bs analysis, we employed a CD4-Fc
construct and the five CD4bs mAbs VRC01, VRC03, b12,
b13 and F105 (Figure 4 and Additional file 2), which differ
in their neutralizing capacity and their steric hindrance in
binding to native trimers. NL4-3 gp140 is most reactive
with all constructs targeting the CD4bs. In contrast, the
NL4-3/ADA hybrid shows massively reduced reactivity of
its CD4bs despite the presence of all critical elements of
the discontinuous epitope (Additional files 1 and 2). While
moderate binding to CD4-Fc and b13 mAb is still ob-
served, the hybrid NL4-3/ADA gp140 almost completely
lost its accessibility for the other CD4bs mAbs compared
to its parental NL4-3 and ADA gp140 constructs. Al-
though only one amino acid (aa 277 T ->N) is changed
within the epitope for some CD4bs mAbs (shown for b12,
VRC01 and F105 in Additional file 2), the exchange in the
V3 flanking region contains a total of 11 altered amino
acids (Additional files 1 and 2). This may result in subtlestructural alterations within the conformationally sensitive
CD4bs resulting in reduced binding and activation by
CD4 and CD4bs mAbs.
3D reconstruction of NL4-3 and NL4-3/ADA gp140 trimers
Using electron microscopy and single particle analysis,
we generated 3D reconstructions from trimeric NL4-3
(EMDB 2657 [43]) and NL4-3/ADA gp140 (EMDB 2659
[44]). Gp140 density maps were generated from nega-
tively stained single particles through an iterative pro-
cedure of 3D alignment, classification, and averaging
using about 3,000 particles per data set (see random se-
lection in Additional file 7). By these means we obtained
structural information from trimeric Env derived from
an X4 HIV-1 strain and observed for the first time the
effects of exchanging the V3 spanning region on the
overall trimer structure at the given resolution of ~25 Å
(Figure 5; NL4-3 in grey, NL4-3/ADA in cyan). In side
view, the structures display an open upper part with
three masses that are connected with one bridge each to
Figure 5 3D reconstruction of NL4-3 and NL4-3/ADA gp140
trimers. Density maps of NL4-3 gp140 trimer (grey) and NL4-3/ADA
gp140 trimer (cyan) viewed along (A, top view) and perpendicularly
to its threefold symmetry axis (B, side view). Both density maps
show a trimeric propeller-like Env architecture with an open
conformation. The three masses are only connected in the lower
part. The bottom row depicts the superposition of the density maps.
Note the high overall congruency; the subtle differences in the tilting
of the upper masses and the rotation of the triangular lower mass are
not significant at the present resolution of 25 Å.
Figure 6 Fitting of gp120 X-ray structures into NL4-3 and
NL4-3/ADA gp140 density maps. Automated fitting of a gp120
X-ray structure (pdb 2NY7) into NL4-3 (grey) and NL4-3/ADA gp140
density maps (cyan), viewed from top (A) and side view (B). In the
bottom row, the 3D model of NL4-3 gp140 is shown with the locations
of the V3 loop and the CD4 binding site indicated with green and
yellow balls, respectively. Magenta balls represent the N- and
C-terminal stumps of gp120. The bridging sheets are colored in blue.
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masses are directed upwards and are almost parallel to
the three-fold symmetry axis. Viewed from the top
(Figure 5A), the density maps have a propeller-like ap-
pearance. The upper masses are located laterally to the
central lower mass with its apices tilting sideways and
for NL4-3/ADA also slightly outwards. Superposition of
both density maps (Figure 5, bottom row) reveals that
they clearly resemble each other in their overall architec-
ture. Whether the small differences between both dens-
ity maps in tilt and rotation angle of the four masses are
significant is not clear at the present resolution.
Docking of unliganded NL4-3 and NL4-3/ADA gp140
At the mass-corrected threshold, the three protruding
masses of both 3D reconstructions resembled an unli-
ganded gp120 molecule in size and overall shape (see forexample pdb-ID 2NY7 [45]). Copies of the latter were
docked as follows (Figure 6): First, the gp120 structures
were oriented manually with their N- and C-terminus
(magenta spheres in Figure 6 bottom row) directing to-
wards the single larger central mass, which is supposed
to represent the ectodomain of gp41. After this pre-
orientation, automated rigid-body fitting yielded a stable
result, with the N-glycosylation sites (spheres in Add-
itional file 8) and the CD4 binding sites (yellow spheres
in Figure 6 bottom row) pointing outwards. Significantly,
with these sites pointing inwards, stable automated
docking was not achieved. This result was obtained with
both 3D reconstructions. In both cases, the only stable
alternative was with the N- and C-termini pointing 180°
away, i.e. opposite to the supposed ectodomain, which
can be excluded for structural reasons. The allocation of
the V3 loops and the bridging sheet are indicated with
green spheres and blue beta sheets, respectively (Figure 6
bottom row and its animated version in Additional file
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vealed that their docked X-ray structures were almost
superimposed (Additional file 10). This underlines their
similarity, as the slight differences are within the reso-
lution limit.
Discussion
In this study, the prototypic X4 NL4-3 TCLA strain [46]
was used to derive soluble uncleaved gp140 constructs
with the parental X4 and a recombinant R5 ADA V3
spanning region for antigenic and structural analyses. V3
exchanges between R5 and X4 HIV-1 were performed
previously and proven to be sufficient to mediate a
change in cell tropism [6,47-49]. An increase in positive
net charge mediated by only a few amino acid changes,
mainly at positions 11, 24 or 25 of the V3 loop, were de-
scribed as being sufficient to shift binding from CCR5 to
the more negatively charged CXCR4 coreceptor [50].
The V3 exchange in our construct resulted in a decrease
in net charge from +9 in the X4 NL4-3 V3 loop (9 posi-
tively R/K/H residues vs. no negatively charged D/E resi-
dues) to +5 in the R5 ADA V3 loop (7 R/K/H vs. 2 D/E)
including an exchange at position 25 from lysine (K) to
aspartic acid (D). As expected, mAb D19, which preferen-
tially binds X4 variants [36], strongly bound to the X4
NL4-3 gp140 construct and the V3 exchange to R5 ADA
reduced D19 binding to levels of the paternal R5 ADA
gp140 according to the expected acquisition of R5 like
properties.
3D reconstructions of both constructs were generated
from purified Env trimers. Thus, the reconstruction of
the complexes was straight forward and no in silico sep-
aration of particles had to be done. As both data sets
were split prior to the reconstruction process noise re-
finement was minimized. Although at the present reso-
lution of ~25 Å structural details still remain obscure,
the overall quaternary architecture can be deduced. The
propeller-like trimer configurations with a common
basal stalk are similar in both constructs and further-
more are congruent to recently published structures of
soluble HIV-1 Env (e.g. [24,29]) and a CD4 independent
SIV Env ([51]; see also Additional file 11). Automated
fitting of the gp120 X-ray structure [45] resulted in a
reasonable location of reference epitopes like the CD4
binding site, V3 loop, coreceptor binding or N-
glycosylation sites (Figure 6 and Additional file 8).
The gp140 construct from the TCLA X4 strain NL4-3
shows a marked open configuration, which resembles the
open architecture of CD4 independent SIV Env [51,52]
but differs considerably from published R5 trimer struc-
tures derived from HIV-1 subtype B [20,21,24,53,54] (see
Additional files 11 and 12). These subtype B R5 structures
share a closed Env configuration with a tight assembly of
the three gp120 protomers at the top. The closed R5conformation was observed for membrane-associated Env
on virions as well as for soluble SOSIP gp140 constructs,
independently of their origin from laboratory-adapted
(Bal) or primary (JRFL) strains. Recently, high resolution
Env structures were achieved from stabilized SOSIP gp140
trimers derived from HIV-1 subtype A strains that are
known as mainly CCR5 tropic [26,30,35]. These structures
also feature a closed conformation at a much higher
resolution.
The X4 gp140 construct in this study is derived from
the laboratory-adapted strain NL4-3 and therefore, the
structure may not reflect the general structure of native
Env from primary X4 strains. Alternatively, the open
structure may rather reflect structural consequences of
lab adaptation. However, the side-by-side comparison of
our X4 NL4-3 and an R5 Bal construct, which are both
derived from laboratory-adapted HIV-1 strains ([53,54],
Additional file 11) reveal marked differences in the
“openness” of the trimers. Thus, despite possible adapta-
tions during in vitro culture eventually resulting in a
more opened Env structure, still X4 Env has a more
open architecture than R5 Env. Therefore, the open
structure of our X4 NL4-3 Env seems to be primarily
due to the X4 phenotype or to inherent features of our
uncleaved gp140 immunogens, rather than to culture
adaptation. Future studies are needed to confirm these
findings with more mature cleaved Env derived from pri-
mary X4 strains.
It has been known for long time that TCLA viruses
are more sensitive to antibody neutralization than pri-
mary strains and it was assumed that this correlates with
better accessibility of critical antibody epitopes [55].
However, by using genetically related primary and TCLA
viruses, it was shown that their differential neutralization
profiles are not related to differences in antibody accessi-
bility and binding but rather result from differences in
subsequent entry processes [56]. SHIV macaque models
of HIV-1 suggest that the evolution of X4 viruses in vivo
requires an opening of Env as an early event during cor-
eceptor switch that mediates better access to CD4 and
moreover an increased neutralization sensitivity by
CD4bs antibodies [57,58]. Accordingly, our ELISA ana-
lyses revealed an enhanced accessibility of the CD4bs
from the X4 NL4-3 construct in comparison to R5 ADA
(Figure 4). We consistently observed higher binding of
the five CD4bs mAbs VRC01, VRC03, b12, b13 and
F105 as well as CD4-Fc to NL4-3 gp140. Additionally,
both coreceptor binding site antibodies, 17b (Additional
file 4) and CG10 (Figure 2), the latter being strictly CD4
dependent, exhibited an increased maximum binding
capacity for NL4-3 gp140 compared to ADA gp140
upon CD4 activation. Notably, the less CD4 dependent
mAb 17b, which even can induce the expression of the
coreceptor binding sites in the absence of CD4 in
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[32], does not exhibit preferential binding to NL4-3
gp140 without prior CD4 activation. Thus, better anti-
body access to X4 NL4-3 gp140 is mainly observed for
mAbs involving the CD4bs, however this is also true for
the gp41 mAbs tested in this study including the trimer
specific mAb Md-1.
The NL4-3/ADA hybrid shows considerable reactivity
with V3 and gp41 antibodies, which is comparable to
that of the ADA construct for mAb D19 and Md-1. Sur-
prisingly, the exchange of the V3 region resulted in sub-
stantially enhanced binding of mAb 447-52D, directed
against the tip of V3. Similar kon rates in combination
with significantly decreased koff rates (Figure 3 and
Additional file 6) are indicative of structural constraints
impairing antibody dissociation from the hybrid NL4-3/
ADA construct resulting in increased overall binding by
ELISA (Figure 2). There is also binding of the hybrid
construct to CD4 (CD4-Fc), although strongly reduced
with respect to ADA and NL4-3 Env (Figure 4). This is
remarkable, as the CD4bs core epitope in the mutant
construct is identical to that of the NL4-3 construct and
there is only one exchange of a threonine to asparagine
at position 277 affecting some CD4bs mAb epitopes (see
Additional file 2). According to the presence or absence
of aa 277 in the respective CD4bs mAb epitopes, we ob-
serve different degrees of CD4bs mAb binding ranging
from very weak/absent binding (e.g. b12, F105, VRC01)
to binding comparable to ADA gp140 (b13). Of note, ei-
ther amino acid at this position works for efficient CD4
and CD4bs mAb binding in their parental NL4-3 or
ADA strains. Therefore, it seems likely that our “artifi-
cial” combination of two themselves functional CD4
binding sites (NL4-3 and ADA) leads to an altered con-
formational arrangement of the epitope that limits CD4/
CD4bs antibody binding or accessibility [32,59,60]. Con-
sequently, also binding of CD4i mAbs to NL4-3/ADA is
drastically reduced (CG10) or absent (17b).
Although this impaired CD4 activation capacity of the
NL4-3/ADA hybrid does not allow us to draw any func-
tional conclusions or to address the degree of “openness”
by correlations to CD4bs antibody reactivities, it is re-
markable that the exchange of the V3 spanning region of
X4 NL4-3 for that of R5 ADA did not abrogate the open
conformation of the NL4-3 Env. Despite the fact that
the V3 exchange resulted in the expected reduced bind-
ing of mAb D19 in the NL4-3/ADA hybrid comparable
to that of R5 ADA, the overall structure still resembled
the original NL4-3 trimer. Thus, multiple mutations at
different sites in and outside the NL4-3 V3 may contrib-
ute to the open conformation of the NL4-3 gp140 con-
struct, which might partially reflect the documented
adaptations of X4 viruses during the process of corecep-
tor switch [61,62].Conclusions
In our study, the soluble NL4-3 HIV-1 gp140 construct
served as an immunogenic mimic of a prototypic T-cell
line-adapted X4 strain. This is the first 3D reconstruc-
tion of an X4 gp140 trimer. It displayed a remarkably
open propeller-like structure, contrasting with recent
more closed R5 HIV-1 Env structures. Structural studies
with higher resolution using either soluble cleaved tri-
meric Env mimetics or virus bound native Env spikes
from different primary X4 strains are needed to deter-
mine if the open conformation is a common feature of
X4 viruses. Structural studies with recombinant Env tri-
mers combined with functional studies of the respective
viruses would further help to elucidate the contribution
of different Env regions with regard to coreceptor choice
and cell culture adaptation.
Methods
Cloning of gp140 constructs
ADA gp140 was cloned as described previously [17]. For
2F5 binding analyses, an ADA gp140 construct was used
with extended 19 aa at its C-terminus (encoding for the
complete MPER region) and additional 6× His tag. Clon-
ing of NL4-3-gp140 was performed similarly, including
the complete MPER region at the C-terminus. For de-
tails see Additional file 13.
Recombinant expression and purification of gp140
Recombinant expression was performed in CHO-
Lec3.2.8.1 cells for ADA gp140 [17]. NL4-3 gp140 was
expressed similarly in CHO-K1 cells (Lonza) or CHO-
Lec1 cells (ATCC) with no effects on structural out-
come. Stably transfected cells were induced for expres-
sion with 4 mM sodium butyrate and supernatants were
harvested after six days. Genomic DNA preparations
from the stably gp140 expressing cell lines confirmed
the integrity of the expression constructs. In addition to
stable expression of gp140 proteins, transient expres-
sions were performed (CHO-K1 cells, Lonza) that were
similar in outcome concerning biochemical analysis but
superior for structural analysis. Supernatants of transient
expressions were harvested two days after transfection.
For purification of gp140 trimers, sequential purification
steps were performed beginning with Galanthus nivalis
lectin (Sigma) batch purification and elution with 0.5 M
Methyl-α-D-mannopyranoside. The second purification
step consisted of size-exclusion chromatography or gly-
cerol gradient centrifugation. For size exclusion chroma-
tography we run a HiLoad™ 16/60 Superdex™ 200 prep
grade column (GE Healthcare) at 0.4 ml/min with 0.5
fraction size on an Äkta chromatography system. Glycerol
gradient centrifugations were performed with a 10 - 30%
glycerol gradient and a 5% glycerol cushion in 4 ml Beck-
man Polyallomer UZ tubes in a SW60TI rotor and
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third purification step was necessary to get purified tri-
mers. An anion-exchange chromatography on a HiTrap™
DEAE FF column was run with 0.5 ml/min flow rate and
0.5 ml fraction size. After each purification step, target
fractions were concentrated and rebuffered with size
exclusion filters (Amicon, 100 kDa cut off) in an appropri-
ate buffer.
ELISA
ELISA plates (high binding; Greiner) were coated over
night at 4°C with purified trimeric gp140 proteins,
monomeric gp120 proteins or BSA as negative control
(100 ng per well). For analysis of CD4 induced epitopes
by CG10 or 17b, 100 ng gp140 proteins and BSA were
preincubated with 20 ng soluble 2 domain CD4 (Sino
Biological Inc.) for 30 min at 37°C before coating. Plates
were blocked after the first incubation step with 1% BSA
(Serva) in PBS (Lonza) for at least 1 h at room
temperature. For detection, monoclonal antibodies D19
(from Patricia Earl), CG10 (from Jon Gershoni), 17b,
VRC01, VRC03, b13, F105, Md-1 (NIH), 447-52D, b12,
2F5, 246-D (from Polymun) as well as CD4-Fc (Abcam)
were applied in 8 different concentrations between 0
and 10 nM or in different dilutions as indicated. α-p24
serum dilutions were used as negative control. Antibodies
were incubated in PBS/0.1% Tween/0.1% BSA (B-PBS-T)
for 1.5 h at room temperature. HRP-labeled α-human IgG
or α-mouse IgG (for CG10 and α-p24) secondary anti-
bodies were used 1:5,000 for 1 h at room temperature
in B-PBS-T followed by chemiluminescence imaging.
Between all incubations, the plates were washed three
times with 300 μl PBS/0.1% Tween per well. Nonlinear
regression fits were applied to the binding curves and
KD values were derived if applicable (PRISM software).
Surface plasmon resonance (SPR) spectroscopy
Antibody binding experiments were performed on a Pro-
teOn XPR36 system (Bio-Rad) at a constant temperature of
23°C. The evaluation was done with ProteOn Manager™ 3.1
software. As ligand, mAb 447-52D (200 μl, 0.015 mg/ml,
pH 4.5) was immobilized on a ProteOn™ GLC Sensor Chip
(Bio-Rad). As analytes, the gp140 proteins were injected in
different concentrations from 0–200 nM (100 μl each). The
association time was set to 60 s, the dissociation time to
300 s and the flow rate was 100 μl/min. The measured sen-
sorgrams were fitted with a Langmuir binding model.
Electron microscopy, 3D reconstruction and visualization
Samples were diluted to the final concentration
(~0.02 mg/ml) and negatively stained on previously glow
discharged (25 mA for 30 s) continuous carbon 200 mesh
grids (Science service, Munich) using 2% uranyl formate.
Grids were then transferred to a Tecnai12 transmissionelectron microscope operating a LaB6 electron source at
120 kV. Images were acquired at a nominal magnifica-
tion of 71540× using a 4k×4k (bin 2) CCD camera
(TVIPS, Munich) with a final resolution of 4.36 Å/pixel.
Image processing was performed on a 358 core AMD
Opteron computer cluster. Particles were selected using
the Appion [63] manual picker and Gaussian noise balls
were used as starting models for half datasets. The half
datasets were independently refined until no further im-
provement was seen using EMAN [44] and only com-
bined for the last model building. As particles from the
expected size were purified C3 symmetry was applied.
During the refinement a spherical mask was applied and
a final angular increment of 5° was used. The final 3D
density maps were filtered to their resolution as deter-
mined by the FSC1/2-bit criterion (25 Å) (for further details
and references, see [64]). The threshold was approxi-
mately mass-corrected (assuming 3 × 140 = 420 kDa) for
displaying. Visualization of density maps and the subse-
quent structural analysis, such as docking of the X-ray
structure, was done using UCSF Chimera [65].Ethics statement
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